Evidence map›Paper›PMID 35631145›Full record

Trial reportNutrients2022

Comparing Digital Therapeutic Intervention with an Intensive Obesity Management Program: Randomized Controlled Trial.

Katarína Moravcová, Martina Karbanová, Maxi Pia Bretschneider, Markéta Sovová, Jaromír Ožana, Eliška Sovová

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 4 pooled it
9.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Observational
  9. Review
  10. Review
  11. Article
  12. Review
  13. Adoption of Digital Therapeutics in Europe.Therapeutics and clinical risk management · 2024
    Review
  14. Article
  15. Article
  16. Medical Telemonitoring for the Management of Hypertension in Older Patients in Japan.International journal of environmental research and public health · 2023
    Review
  17. Article
  18. Article
  19. IntroducingNutrients · 2022
    Article
  20. Article
4 · The record

Corrections and comments

  • Commented on by
    2023
5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Katarína MoravcováDepartment of Exercise Medicine and Cardiovascular Rehabilitation, University Hospital Olomouc, I. P. Pavlova 6, 779 00 Olomouc, Czech Republic.
Martina KarbanováDepartment of Health, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
Maxi Pia BretschneiderDepartment for Prevention and Care of Diabetes, Department of Medicine III, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Germany.ORCID 0000-0002-3962-4908
Markéta SovováDepartment of Exercise Medicine and Cardiovascular Rehabilitation, University Hospital Olomouc, I. P. Pavlova 6, 779 00 Olomouc, Czech Republic.
Jaromír OžanaDepartment of Exercise Medicine and Cardiovascular Rehabilitation, University Hospital Olomouc, I. P. Pavlova 6, 779 00 Olomouc, Czech Republic.
Eliška SovováDepartment of Exercise Medicine and Cardiovascular Rehabilitation, University Hospital Olomouc, I. P. Pavlova 6, 779 00 Olomouc, Czech Republic.
University Hospital Olomouc · CZCharles University · CZTechnische Universität Dresden · DE

Funding

Palacký University Olomouc, Czech Republic IGA_LF_2020_030
6 · The paper itself

Abstract

In this study, we evaluated whether the digital program Vitadio achieves comparable results to those of an intensive in-person lifestyle intervention in obesity management. This is a 12-month prospective, randomized controlled trial. Obese patients with insulin resistance, prediabetes or type 2 diabetes were included. The intervention group (IG) used Vitadio. The control group (CG) received a series of in-person consultations. Body weight and various metabolic parameters were observed and analyzed with ANOVA. The trial is ongoing and the presented findings are preliminary. Among 100 participants (29% men; mean age, 43 years; mean BMI, 40.1 kg/m2), 78 completed 3-month follow-up, and 51 have completed the 6-month follow-up so far. Participants significantly (p < 0.01) reduced body weight at 3 months (IG: −5.9 ± 5.0%; CG: −4.2 ± 5.0%) and 6 months (IG: −6.6±6.1%; CG: −7.1 ± 7.1%), and the difference between groups was not significant. The IG achieved favorable change in body composition; significant improvement in TAG (−0.6 ± 0.9 mmol/l, p < 0.01), HDL (0.1 ± 0.1%, p < 0.05), HbA1c (−0.2 ± 0.5%, p < 0.05) and FG (−0.5 ± 1.5 mmol/l, p < 0.05); and a superior (p = 0.02) HOMA-IR reduction (−2.5 ± 5.2, p < 0.01). The digital intervention achieved comparable results to those of the intensive obesity management program. The results suggest that Vitadio is an effective tool for supporting patients in obesity management and diabetes prevention.

Indexed as

Diabetes Mellitus, Type 2Insulin ResistanceObesity ManagementAdultBody WeightFemaleHumansMaleObesityProspective Studiesdiabetes mellitus type 2digital therapeuticsinsulin resistancelifestyle interventionmetabolic syndromemobile applicationobesitypreventionrandomized controlled trial

Identifiers

PMID35631145
PMCPMC9143861
OpenAlexW4280607715

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.